Author: Roberto, Palumbo; Francesco, Londrino; Emanuela, Cordova; Giorgia, Gambardella; Pasquale, Niscola; Sara, Dominijanni
Title: Current treatment of COVID-19 in renal patients: hope or hype? Cord-id: look6ddt Document date: 2020_9_28
ID: look6ddt
Snippet: To date the severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2), known as COVID-19, is for clinicians the most difficult global therapeutic problem. In this landscape, the management of patients with chronic kidney disease, acute kidney injury or patients undergoing immunosuppressant therapies for kidney transplant or glomerular diseases, represent a clinical challenge for nephrologists, especially in patients with severe acute lung involvement. Therefore in this setting, due to the la
Document: To date the severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2), known as COVID-19, is for clinicians the most difficult global therapeutic problem. In this landscape, the management of patients with chronic kidney disease, acute kidney injury or patients undergoing immunosuppressant therapies for kidney transplant or glomerular diseases, represent a clinical challenge for nephrologists, especially in patients with severe acute lung involvement. Therefore in this setting, due to the lack of anti-COVID treatment schedules, tailored management is mandatory to reduce the side effects, as consequence of impaired renal function and drugs interactions. We report the main treatment actually used against SARS-CoV-2, underlining its possible use in the nephropatic patients and the central role of nephrologists to improve the clinical outcome.
Search related documents:
Co phrase search for related documents- action mechanism and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- action mechanism and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- action mechanism and acute severe pneumonia: 1, 2, 3
- action mechanism and adenosine nucleotide analogue: 1, 2
- active site and acute ards respiratory distress syndrome: 1, 2
- active site and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- active site and acute severe pneumonia: 1
- active site and liver dysfunction: 1
- activity broad spectrum and acute ards respiratory distress syndrome: 1, 2, 3
- activity broad spectrum and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- activity broad spectrum and adenosine nucleotide analogue: 1
- activity broad spectrum and administration 10 day: 1
- acute aki kidney injury and adjusted dose: 1, 2
- acute aki kidney injury and liver dysfunction: 1, 2, 3, 4, 5, 6
- acute ards respiratory distress syndrome and adjusted dose: 1
- acute ards respiratory distress syndrome and liver dysfunction: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- acute ards respiratory distress syndrome and liver eliminate: 1
- acute respiratory syndrome and adjusted dose: 1, 2, 3, 4, 5, 6, 7, 8
- acute respiratory syndrome and liver eliminate: 1
Co phrase search for related documents, hyperlinks ordered by date